tissue-based diagnostics Foundation Medicine Probing Tumor Fraction Influence on Negative Liquid Biopsies Premium The company has published evidence that its TF estimation technique could potentially guide clinical follow-up decisions in cases with a negative liquid biopsy result. Fulgent Genetics Preliminary Q1 Revenues Exceed Guidance; Firm to Acquire Inform Diagnostics Fulgent plans to leverage the Texas-based pathology lab's established commercial organization and managed care relationships. Qiagen, Mirati Therapeutics Partner to Develop KRAS Companion Test for NSCLC Drug The tissue-based test will identify cancer patients who may benefit from adagrasib, Mirati's investigational oral small molecule inhibitor of KRAS G12C. UK Startup Gabriel Precision Oncology Leans on Congenica to Broaden NGS Use in Cancer Testing Premium Spun out of the Glasgow Precision Oncology Laboratory, Gabriel wants targeted sequencing to become the norm for all somatic cancer patients. Representative Tumor Sampling Method Promises to Lessen Bias of Molecular Analyses Premium The method, called representative sequencing, homogenizes chunks of leftover tumor tissue following pathology extraction to capture an unbiased profile of the tumor's cellular heterogeneity. Apr 27, 2020 FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics Feb 10, 2020 Through Mayo Clinic Pact, PGDx Hopes to Show Clinical Utility for NGS Tissue, Liquid Biopsy Assays Premium Jan 15, 2020 JP Morgan Healthcare Day 2: 10x Genomics, GenapSys, Caris, Adaptive Bio, Danaher, Agilent, Luminex Jul 25, 2019 Roche Reports Flat Diagnostics Revenues in H1 Apr 17, 2019 Roche Reports Flat Q1 Diagnostics Sales Jan 19, 2018 RNA Hybridization, Multiplex Assays Central to Bio-Techne's Growth Plans Premium Dec 9, 2016 Novartis PI3K Inhibitor Effective in Breast Cancer Subset; Psych Toxicities Dampen Enthusiasm Premium Jul 15, 2016 Ethics, Guidelines for Molecular Autopsy in Youth Sudden Death Explored by Texas Team Dec 23, 2014 Now Part of AstraZeneca, Definiens Concentrating on CDx, Ramp up into Clinical Space Premium Dec 10, 2014 Roche Buys Tissue Dissection Technology from AvanSci Bio Jun 23, 2014 Definiens Raises $20.4M in Private Financing Round Jun 25, 2013 TGen, Ventana Ink Pancreatic Cancer Biomarker Pact Mar 12, 2013 Leica, Synthon Biopharmaceuticals Partner on CDx Development Feb 15, 2013 FDA Clears ASI Gene Scanner as PGx Tool for NSCLC Feb 12, 2013 Dako, Pfizer Reach Companion Dx Deal Sep 6, 2012 Agilent Discloses Dako Earnings May 17, 2012 Agilent Buying Cancer Diagnostics Company Dako for $2.2B May 1, 2012 Dako, Genentech Partner on Regulatory Submission of CDx for Second Breast Cancer Drug Apr 30, 2012 GE Grant Funds Moffitt Breast Cancer Metastasis Marker Study Apr 27, 2012 MetaStat Licenses Metastatic Cell Dx Technology Patents Load More Breaking News Ceres Nanosciences Wins $1.4M in NIH RADx Funding for Additional Wastewater Epidemiology Centers Study Unearths Features Found in Long-Term Survivors of Advanced Ovarian Cancer GenomeWeb Top 40 up 8 Percent in November, Outpacing Broader Market Oxford Nanopore Technologies, Bio-Techne Partner to Develop Carrier Screening Assay ERS Genomics Licenses CRISPR-Cas9 IP to Cosmo Bio The Scan New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability. Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances. New mRNA Vaccines Offer Hope for Fighting Malaria A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines. Unique Germline Variants Found Among Black Prostate Cancer Patients Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.